ORPHA:79258
Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia
Also known as: G6P deficiency type 1a · GSD due to G6P deficiency type 1a · GSD due to G6P deficiency type Ia · GSD type 1a · GSDIa · Glycogen storage disease due to G6P deficiency type Ia · Glycogen storage disease type 1a · Glycogenosis due to glucose-6-phosphatase deficiency type 1a · Glycogenosis due to glucose-6-phosphatase deficiency type Ia · Glycogenosis type Ia
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
1,266
Trials
5
Interventional, condition-specific
Researchers
1,192
Distinct authors in sample
Gene link
G6PC1
Definitive
Readiness
6/6
Stages with a signal
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0009287
- MeSH:C538655
- OMIM:232200
- UMLS:C2919796
Additional Mondo synonyms (8)
G6PC glycogen storage disease · glycogen storage disease caused by mutation in G6PC · glycogen storage disease due to G6P deficiency type Ia · glycogen storage disease type 1a · glycogen storage disease type Ia · glycogenosis due to glucose-6-phosphatase deficiency type 1a · glycogenosis due to glucose-6-phosphatase deficiency type Ia · glycogenosis type Ia
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
6/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — G6PC1
- LiteraturePresent
1,266 matched papers (827 in last 10 years) Source
- Phenotype characterisedPresent
28 HPO annotations (e.g. Abnormal bleeding; Hyperlipidemia; Hepatomegaly) Source
- Animal modelPresent
5 genotype models (Mus musculus) Source
- Orphan designationPartial
2 EMA designations (none yet with FDA orphan-indication approval) — e.g. adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase gene (pariglasgene brecaparvovec) Source
- Interventional trialPresent
5 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (G6PC1).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
28
Associated phenotypes · MONDO:0009287
- Abnormal bleeding
- Hyperlipidemia
- Hepatomegaly
- Elevated circulating hepatic transaminase concentration
- Intermittent diarrhea
Showing 5 of 28 — open Monarch for the full list.
Animal models (Monarch / Alliance)
5
Model associations linked to this Mondo ID
- G6pc1tm1Jyc/G6pc1tm1Jyc [background:] involves: 129S4/SvJae·MGI:2677133·Mus musculus
- G6pc1em1Jyc/G6pc1em1Jyc [background:] involves: 129S4/SvJae * C57BL/6·MGI:7506311·Mus musculus
- G6pc1tm2.2Jyc/G6pc1tm2.2Jyc [background:] involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6J * FVB/N·MGI:4418690·Mus musculus
- G6pc1tm1.1Ics/G6pc1tm1.1Ics Tg(Kap-cre/ERT2)64.9Ics/0 [background:] involves: 129S2/SvPas * FVB/N·MGI:5823404·Mus musculus
- G6pc1tm1.1Ics/G6pc1tm1.1Ics Albtm1(cre/ERT2)Mtz/Alb+ [background:] involves: 129S2/SvPas * C57BL/6J·MGI:5478556·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
2
Designations · no FDA orphan-indication approval yet
- EMA adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase gene (pariglasgene brecaparvovec)treatment of glycogen storage disease type Ia · 18/11/2016 · PositiveEMA designation
- EMA mRNA encoding human glucose-6-phosphatase variant S298Ctreatment of glycogen storage disease type Ia · 14/01/2022 · PositiveEMA designation
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
9
Drugs / clinical candidates · MONDO_0009287
- PARIGLASGENE BRECAPARVOVEC·phase 3
- BETAMETHASONE·phase 1 2
- BETAMETHASONE SODIUM PHOSPHATE·phase 1 2
- DEXAMETHASONE·phase 1 2
- HYDROCORTISONE·phase 1 2
- METHYLPREDNISOLONE·phase 1 2
- PREDNISOLONE·phase 1 2
- PREDNISONE·phase 1 2
- TRIAMCINOLONE·phase 1 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,266
1,266 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,266 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
827 in the last 10 years · low confidence
Phrase hits: 957 · MeSH hits: 0
Who's working on it?
1,192
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Derks TGJ14 papers · 2026
Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Papers in Europe PMC - 02Oosterveer MH11 papers · 2026
Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Papers in Europe PMC - 03Rossi A10 papers · 2025
Department of Translational Medicine, Section of Pediatrics, University of Naples "Federico II", Naples, Italy.
Papers in Europe PMC - 04Mithieux G8 papers · 2026
Institut National de la Santé et de la Recherche Médicale, U1213, Lyon, F-69008, France; Université de Lyon, Lyon, F-69008, France; Université Lyon1, Villeurbanne, F-69622, France. Electronic address: gilles.mithieux@univ-lyon1.fr.
Papers in Europe PMC - 05Rajas F8 papers · 2026
Institut National de la Santé et de la Recherche Médicale, U1213, Lyon, F-69008, France; Université de Lyon, Lyon, F-69008, France; Université Lyon1, Villeurbanne, F-69622, France. Electronic address: fabienne.rajas@univ-lyon1.fr.
Papers in Europe PMC - 06Weinstein DA8 papers · 2026
Glycogen Storage Disease Program, Connecticut Children's Medical Center, Hartford, Connecticut.
Papers in Europe PMC - 07Chou JY7 papers · 2026
Section on Cellular Differentiation, Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA. Electronic address: chouja@mail.nih.gov.
Papers in Europe PMC - 08Melis D7 papers · 2025
Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", Section of Pediatrics, University of Salerno, Via Salvador Allende, 43 84081, Baronissi (Salerno), Italy. dmelis@unisa.it.
Papers in Europe PMC - 09Parenti G7 papers · 2025
Department of Translational Medicine, Section of Pediatrics, University of Naples "Federico II", Naples, Italy.
Papers in Europe PMC - 10Arnaoutova I6 papers · 2025
Section on Cellular Differentiation, Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
5
interventional trials for this specific condition
5 interventional trials matched this specific condition name; 1 currently recruiting in our sample.
Data as of 11 September 2026 · last trial check 28 July 2026
5 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 89.2th percentile).
low confidence · 89.2th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
5 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06735755·RECRUITING·A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
Not reviewed·Conditions: Glycogen Storage Disease Type Ia·Matched via name phrase
Observational and natural-history studies
8 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06636383·RECRUITING·Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
Not reviewed·Conditions: Glycogen Storage Disease Type Ia·Matched via name phrase
- NCT06843330·RECRUITING·Accuracy of Lactate Meter in GSDIa
Not reviewed·Conditions: Glycogen Storage Disease Type Ia·Matched via name phrase
- NCT07459582·RECRUITING·Accuracy of Home Lactate Meter and Accu-chek Glucometer in Patients With Glycogen Storage Disease
Not reviewed·Conditions: Glycogen Storage Disease Type IA · Glycogen Storage Disease Type I · Glycogen Storage Disease Type IB · Glycogen Storage Disease Xi·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26Likely covered — the policy lists Glycogen storage disease type I as a category (Group 1), and this condition is a form of it. Confirm eligibility with a Centre of Excellence.
Group 1 — one-time curative treatment
Up to ₹50 lakh per patient
Financial support for treatment at notified Centres of Excellence (figures evolved from the original ₹20 lakh Group-1 ceiling).
Policy figures change. Verify current MoHFW / CoE guidance before relying on any amount. Verify
Centres of Excellence (15)
- All India Institute of Medical Sciences (AIIMS) — New Delhi, Delhi
- Maulana Azad Medical College — New Delhi, Delhi
- Sanjay Gandhi Post Graduate Institute of Medical Sciences — Lucknow, Uttar Pradesh
- Post Graduate Institute of Medical Education and Research (PGIMER) — Chandigarh, Chandigarh
- Centre for DNA Fingerprinting & Diagnostics with Nizam’s Institute of Medical Sciences — Hyderabad, Telangana
- King Edward Memorial Hospital — Mumbai, Maharashtra
- Institute of Post-Graduate Medical Education and Research (IPGMER) — Kolkata, West Bengal
- Centre for Human Genetics with Indira Gandhi Hospital — Bengaluru, Karnataka
- Institute of Child Health and Hospital for Children (ICH & HC) — Chennai, Tamil Nadu
- All India Institute of Medical Sciences (AIIMS) — Jodhpur, Rajasthan
- Sree Avittam Thirunal Hospital (SAT), Government Medical College — Thiruvananthapuram, Kerala
- All India Institute of Medical Sciences (AIIMS) — Bhopal, Madhya Pradesh
- Regional Institute of Medical Sciences (RIMS) — Imphal, Manipur
- All India Institute of Medical Sciences (AIIMS) — Patna, Bihar
- Assam Medical College & Hospital — Dibrugarh, Assam
Voluntary contributions / crowdfunding (separate from CoE funding): https://rarediseases.mohfw.gov.in/
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia" OR "G6P deficiency type 1a" OR "GSD due to G6P deficiency type 1a" OR "GSD due to G6P deficiency type Ia" OR "GSD type 1a" OR "GSDIa" OR "Glycogen storage disease due to G6P deficiency type Ia" OR "Glycogen storage disease type 1a" OR "Glycogenosis due to glucose-6-phosphatase deficiency type 1a" OR "Glycogenosis due to glucose-6-phosphatase deficiency type Ia" OR "Glycogenosis type Ia" OR "G6PC glycogen storage disease" OR "glycogen storage disease type Ia") OR (MESH:"Hepatorenal form of glycogen storage disease") OR ("G6PC1" OR "G6PC1 syndrome" OR "G6PC1-related")MeSH descriptor terms unioned into the query: Hepatorenal form of glycogen storage disease
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia" OR "G6P deficiency type 1a" OR "GSD due to G6P deficiency type 1a" OR "GSD due to G6P deficiency type Ia" OR "GSD type 1a" OR "GSDIa" OR "Glycogen storage disease due to G6P deficiency type Ia" OR "Glycogen storage disease type 1a" OR "Glycogenosis due to glucose-6-phosphatase deficiency type 1a" OR "Glycogenosis due to glucose-6-phosphatase deficiency type Ia" OR "Glycogenosis type Ia" OR "G6PC glycogen storage disease" OR "glycogen storage disease type Ia" OR "Hepatorenal form of glycogen storage disease"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 5 interventional · 8 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: glycogen storage disease caused by mutation in G6PC
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1266) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T02:09:25.655Z
